Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hopeTwo antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can Share XLilly and GSK/Vir antibody pairing offers resistant COVID-19 hopehttps://pharmaphorum.com/news/lilly-and-gsk-vir-antibody-pairing-offers-resistant-covid-19-hope/
GSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rivalGlaxoSmithKline and partner Vir Biotechnology are to expand a trial of an experimental antibody to treat COVID-19, putting Share XGSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rivalhttps://pharmaphorum.com/news/gsk-and-vir-expand-covid-19-antibody-trial-after-trumps-treatment-with-regenerons-rival/
GSK and Vir take COVID-19 antibody therapy into clinicGlaxoSmithKline and US-based Vir Biotechnology are to trial a new therapy for COVID-19 based on an antibody designed Share XGSK and Vir take COVID-19 antibody therapy into clinichttps://pharmaphorum.com/news/gsk-and-vir-take-covid-19-antibody-therapy-into-clinic/
